Skip to main content
. Author manuscript; available in PMC: 2025 Feb 16.
Published in final edited form as: J Magn Reson Imaging. 2021 Feb 15;54(1):251–260. doi: 10.1002/jmri.27557

TABLE 3.

Functional Tumor Volume Measurements in Patients With and Without Pathologic Complete Response (pCR)

Measure Optimal threshold AUC [95% CI] P Mean ± SD volume, cm3
pCR Non-pCR
BL Scan
 FTV1-min PE > 0
SER > 0
0.59 [0.45,0.74] 0.23 15 ± 31 19 ± 24
 FTV2.5-min PE > 0
SER > 0
0.60 [0.46,0.75] 0.18 15 ± 35 18 ± 22
 FTVOpt Early Phase = 30 s
PE > 0
SER > 1.3
0.69 [0.55,0.82] <0.05 0.12 ± 0.34 0.32 ± 0.62
C4 scan
 FTV1-min PE > 40
SER > 0.5
0.85 [0.74,0.95] <0.05 0.12 ± 0.25 3.2 ± 6.2
 FTV2.5-min PE > 95
SER > 0.8
0.83 [0.72,0.94] <0.05 0.17 ± 0.47 2.7 ± 5.4
 FTVOpt Early Phase = 60 s
PE > 40
SER > 0.35
0.85 [0.75,0.96] <0.05 0.13 ± 0.26 3.5 ± 7.2
%C4/BL % change % change
 FTV1-min PE > 130
SER > 1.1
0.82 [0.71,0.93] <0.05 −99% ± 0.20% −89% ± 7.0%
 FTV2.5-min PE > 120
SER > 0.85
0.79 [0.66,0.91] <0.05 −93% ± 24% −62% ± 63%
 FTVOpt Early Phase = 60 s
PE > 115
SER > 0.75
0.85 [0.74,0.95] <0.05 −100% ± 1.7% −47% ± 110%

AUC, area under the receiver operator characteristic curve; BL, baseline; CI, confidence interval; NA, not applicable; ETV, enhanced tumor volume; FTV, functional tumor volume; PE, percentage enhancement; SER, signal enhancement ratio; Opt, optimal; C4, cycle 4.